Wijkhuisen A, Sagot M A, Frobert Y, Créminon C, Grassi J, Boquet D, Couraud J Y
CEA, Service de Pharmacologie et d'Immunologie, DSV/DRM, Gif-sur-Yvette, France.
FEBS Lett. 1999 Mar 26;447(2-3):155-9. doi: 10.1016/s0014-5793(99)00298-7.
The three mammalian tachykinins, substance P (SP), neurokinin A (NKA) and neurokinin B (NKB), exert their physiological effects through specific receptors, NK1, NK2 and NK3, respectively. However, homologous binding studies have recently demonstrated that, contrary to the generally accepted belief, NKA could bind NK1 receptor with high affinity (Hastrup and Schwartz, 1996). Using COS-7 cells expressing the human NK1 receptor, we show that two simultaneous point mutations (E193L and V195R) in a restricted five amino acid sequence (the (193-197) region), selected because of its hydropathic complementarity with the common C-terminal extremity of tachykinins, abolish both the high-affinity binding and highly potent biological activity of NKA, without affecting those of SP. In addition, the same mutations also suppressed the high functional activity of septide, a synthetic SP atypical agonist ([pGlu6-Pro9] SP 6-11). These results suggest that the (193-197) region, located at the end of the second extracellular loop of the receptor, could be part of a common high-affinity binding domain for both NKA and septide, distinct from the SP binding site.
三种哺乳动物速激肽,即P物质(SP)、神经激肽A(NKA)和神经激肽B(NKB),分别通过特异性受体NK1、NK2和NK3发挥其生理作用。然而,同源结合研究最近表明,与普遍接受的观点相反,NKA能够以高亲和力结合NK1受体(哈斯特鲁普和施瓦茨,1996年)。利用表达人NK1受体的COS-7细胞,我们发现,在一个限定的五氨基酸序列((193 - 197)区域)中同时发生的两个点突变(E193L和V195R),因其与速激肽常见的C末端具有亲水性互补性而被选择,这消除了NKA的高亲和力结合和高效生物活性,而不影响SP的活性。此外,相同的突变也抑制了七肽(一种合成的SP非典型激动剂([pGlu6 - Pro9]SP 6 - 11))的高功能活性。这些结果表明,位于受体第二个细胞外环末端的(193 - 197)区域可能是NKA和七肽共同的高亲和力结合域的一部分,与SP结合位点不同。